Publications by authors named "Jota Amarume"
Article Synopsis
- Diabetic retinopathy (DR) is a major cause of vision loss linked to diabetes, prompting a study on the protective effects of pemafibrate in a type 2 diabetes rat model.
- The study involved administering pemafibrate to a group of obese diabetic rats while monitoring their retinal function and health through various examinations, including electroretinography.
- Results indicated that pemafibrate reduced triglycerides and increased good cholesterol, showing improved retinal thickness and larger AQP4-positive areas, suggesting it may help protect against DR.
Effects of Dapagliflozin on Adipose and Liver Fatty Acid Composition and mRNA Expression Involved in Lipid Metabolism in High-Fat-Fed Rats.
Endocr Metab Immune Disord Drug Targets
September 2022
Background: SGLT2 inhibitor enhances not only glucose excretion but also fatty acid utilization. Those facts suggest that SGLT2 inhibitor affects fat accumulation and lipid storage.
Objective: In the present study, we evaluated the effects of dapagliflozin on fatty acid composition and gene expression involved in fatty acid metabolism in rat adipose and liver tissues.
To clarify the effects of long-term administration of SGLT2 inhibitor, a hypoglycemic agent, on basal sympathetic nerve activity (SNA) and on SNA under development of insulin resistance, we measured peripheral SNA in response to a glucose load in standard chow- (SCF) and high-fat-fed (HFF) rats treated with or without dapagliflozin for 7 weeks. We conducted an intravenous glucose administration (IVGA), and evaluated SNA microneurographically recorded in the unilateral sciatic nerve. Dapagliflozin did not affect the steady state action potential (AP) rate just before the IVGA (baseline) in both the SCF and HFF rats.
View Article and Find Full Text PDF